Exenatide
Also known as: Exendin-4, Byetta, Bydureon, Bydureon BCise
Classification
Peptide
Regulatory Status
FDA-approved prescription product
Sources
3
Review
n/a
Overview
Exenatide is a GLP-1 receptor agonist that increases glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying to improve glycemic control in type 2 diabetes.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-approved exenatide products (e.g., Byetta immediate-release; Bydureon extended-release family) are labeled to improve glycemic control in type 2 diabetes as adjuncts to diet and exercise.
Interactions & cautions
Flagged in source data
other GLP-1/dual agonists without prescriber rationale
Drug interactions
insulin or sulfonylureas — Higher hypoglycemia potential in combination. (review)
oral drugs affected by delayed gastric emptying — May alter absorption of some oral medications. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw